Global Influenza Vaccine
Market Report
2025
Influenza Vaccine Market Report 2025 (Global Edition)
Influenza vaccine market is expected to hit $13.29 Billion by 2029 at a growth rate of 8.69%.
The base year for the calculation is 2024. The historical will be 2021 to 2024. The year 2025 will be estimated one while the forecasted data will be from year 2025 to 2033. When we deliver the report that time we updated report data till the purchase date.
PDF Access: Password protected PDF file, Excel File Access: Quantitative data, PPT Report Access: For the presentation purpose, Cloud Access: Secure Company Account Access.
|
Rating: 4.8 | Review: 21
Share your contact details to receive free updated sample copy/pages of the recently published edition of Influenza Vaccine Market Report 2025.
Global Influenza Vaccine Market Report 2025 Market Size Split by Type (Inactivated, Live Attenuated), by Valency (Quadrivalent, Trivalent), by Age Group (Pediatric, Adults), by Distribution Channel (...
According to cognitive market research, the global influenza vaccine market size was valued at USD xx billion in 2024 and is expected to reach USD xx billion at a CAGR of xx% during the forecast period.
- Influenza is one of the community-acquired respiratory infections that can cause significant morbidity in pediatric oncology patients, including hospitalization and secondary bacteremia.
- North America is expected to hold a dominant market share in the forecast period. This is brought about by increased public knowledge of influenza illnesses and the available treatments, and government education initiatives.
- Asia Pacific is anticipated to register the fastest growth rate throughout the forecast period as a result of healthcare reforms.
- In the European influenza vaccine market, advanced healthcare systems and a commitment to public health underscore trends.
- Latin America shows notable growth in the influenza vaccine market.
- The Middle East and Africa played a significant role in the influenza vaccine market. Vaccination can significantly lower seasonal influenza-related risk of infection and illness burden.
| 2024 | 2025 | 2032 | 2033 | CAGR | |
|---|---|---|---|---|---|
| Global Influenza Vaccine Market Sales Revenue | 121212 | 121212 | 121212 | 121212 | 8.69% |
| Base Year | 2024 |
| Historical Data Time Period | 2021-2024 |
| Forecast Period | 2025-2033 |
| Market Split by Type |
|
| Market Split by Valency |
|
| Market Split by Age Group |
|
| Market Split by Distribution Channel |
|
| List of Competitors |
|
| Regional Analysis |
|
Country Analysis |
|
Market Drivers:
| |
Market Restrains:
| |
Market Trends:
| |
Report scope is customizable as we have a huge database of Influenza Vaccine industry. We can deliver an exclusive report Edition/Consultation as per your data requirements. Request for your Free Sample Pages.
Influenza Vaccine Market is Segmented as below. Particular segment of your interest can be provided without any additional cost. Download the Sample Pages!
Influenza Vaccine Market Report Description
Introduction of the Influenza Vaccine Market
Influenza is one of the community-acquired respiratory infections that can cause significant morbidity in pediatric oncology patients, including hospitalization and secondary bacteremia. Furthermore, delayed treatment has been linked to influenza infection, which may have a detrimental effect on the final course of the illness. Vaccines against influenza (flu), sometimes known as "flu shots," protect against four influenza viruses that are expected to be most prevalent in the next season. The majority of flu vaccinations are administered via needle, generally in the arm; however, a nasal spray flu vaccine is also available. Pharmaceutical firms involved in influenza virus research, development, manufacturing, and marketing make up the influenza vaccine industry. The goal of these vaccinations is to increase immunity against both new influenza virus strains that have the potential to trigger pandemics and seasonal influenza.
Trivalent and quadrivalent vaccinations, which offer protection against various influenza virus strains, are available on the influenza vaccine market. To stop the spread of influenza viruses around the world, major companies in this market are working to create better, more potent influenza vaccine formulations. Influenza vaccination is the main tool used to reduce the spread of the virus and illness. As of right now, the United States offers three main forms of influenza vaccinations: recombinant HA protein subunit vaccines, live attenuated influenza vaccines (LAIV), and inactivated influenza vaccines (IIV) (Centres for Disease Control and Prevention, 2021). Various age groups might receive approval for the use of various influenza vaccinations. Furthermore, some vaccinations are not advised for some populations. A person's age, health, and allergies to the influenza vaccine or any of its components are among the factors that might decide whether they are a good candidate for vaccination or immunization with a specific vaccine. People with heart disease who have received the flu vaccination have been shown to have reduced rates of certain cardiac events, particularly if they had experienced a cardiac event within the previous year.
Influenza Vaccine Market Size
Market Dynamics of the Influenza Vaccine Market
Key Drivers of the Influenza Vaccine Market
- Rising global influenza incidences will propel market growth
The rising global incidence of influenza illnesses is a major driver of the influenza vaccine industry. Influenza is a worldwide danger due to factors including urbanization, international travel, and changing virus strains, all of which have contributed to this spike. An acute respiratory infection brought on by influenza viruses is known as seasonal influenza or the flu. It is widespread over the entire planet. Most people heal on their own without medical intervention. People who cough or sneeze with influenza might readily transfer the illness to others. The most effective method of illness prevention is vaccination. Flu symptoms include fever with an abrupt onset, cough, sore throat, body pains, and exhaustion. The goal of treatment should be symptom relief. When they have the flu, people should stay still and hydrate well. The majority of people heal on their own in a week or less. For those with risk factors and in extreme situations, medical attention may be necessary. According to estimates from the World Health Organisation, between 3 and 5 million instances of severe disease occur worldwide each year as a result of influenza outbreaks. Influenza's demographic expansion is another major factor boosting demand for vaccines. There is an increased risk for vulnerable groups, especially children under five, elderly individuals, and those with long-term medical issues. High levels of influenza activity have been observed in the Northern Hemisphere in several countries in Southern Asia, South East Asia, Western Africa, Central America, and the Caribbean, and many of these nations have seen an increase in activity.
(Source:https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal)#:~:text=There%20are%20around%20a%20billion,infections%20are%20in%20developing%20countries. )
- Global immunization initiatives and universal influenza vaccines significantly expand the market growth
Global immunization campaigns, which promote accessibility and broad awareness, are crucial in driving the market for influenza vaccines. International organizations, governments, and pharmaceutical corporations work together to ensure that immunization programs are prioritized and carried out worldwide. The market is growing as a result of these projects' efforts to reach a variety of people, especially in developing nations where there is a growing need for influenza vaccinations. Every year, between February and September, the World Health Organisation (WHO) holds technical consultations to suggest viruses that should be included in seasonal influenza vaccinations for the northern and southern hemispheres, respectively. The WHO Global Influenza Surveillance and Response System, formerly known as the WHO Global Influenza Surveillance Network (GISN), supplied the data on which these guidelines are based.
• For instance, On March 6, 2024, CSL Seqirus, a global leader in public health protection, announced that it is fully prepared to deliver its influenza vaccine portfolio for the 2024-25 season in the US based on their trivalent strains recommended by the FDA’s vaccines and related biological products advisory committee (VRBPAC).
(Source:https://www.cslseqirus.us/news/csl-seqirus-fully-prepared-to-implement-fdas-tiv-strain-selection-for-202425-us-season )
Restraints of the Influenza Vaccine Market
- Vaccine manufacturing complexity and the seasonal nature of demand may hamper the market
The market for influenza vaccines confronts difficulties because of the complex production procedures and the cyclical nature of demand. The production cycle for vaccines is intricate and time-consuming, requiring exact formulation and testing to guarantee safety and efficacy. This procedure's complexity and the strict regulations that surround it add to the manufacturing process' complexity, which makes it more difficult to scale up production quickly in response to unexpected surges in demand during pandemics. The current scarcity of influenza vaccines serves as a timely reminder of how precarious the global vaccine supply is and how manufacturing problems have the potential to seriously impair essential access to life-saving vaccinations. The necessity for quick technical problem-solving and speedy output leads to the complexity of manufacturing processes. Every technology has unique difficulties. Conventional vaccination modalities, such as live-attenuated or inactivated viral vaccines, have well-established manufacturing techniques, but scaling them up takes time. Before the pandemic, novel vaccines like viral vector and mRNA-based vaccines had never been produced on a large scale; as a result, streamlined procedures and specialized knowledge were needed. A major obstacle to the fast production and dissemination of vaccinations based on mRNA was the storage of these vaccines at extremely low temperatures, which required a substantial financial outlay.
• For instance, Pfizer invested $2 billion in late 2020 to build its cold-chain network. As with all innovative approaches, the supporting industry, such as contract development manufacturing organizations (CDMOs, lipid nanoparticle producers) is still nascent and requires time to ramp up production to meet demand.
How Did COVID-19 Impact The Influenza Vaccine Market?
During the pandemic, the COVID-19 epidemic had a major effect on market expansion. During the pandemic, there was a noticeable increase in demand for influenza vaccination due to the respiratory system-affecting effects of SARS-CoV-2. The market's growth was greatly affected by these conditions, which increased demand for influenza vaccinations during the pandemic. For example, the BW story from November 2021 stated that private hospital operators Apollo Hospitals and Fortis Healthcare were also seeing an increase in demand for flu vaccinations, including Abbott's imported vaccine, influvasc. The pandemic-era spike in demand for influenza vaccinations had a significant effect on market expansion. Furthermore, it is anticipated that the demand for the influenza vaccine will not decline throughout the post-pandemic phase, which will support the market's expansion during the projected timeframe.
• For instance, in November 2022, Pfizer, Inc., and BioNTech initiated a phase 1 clinical study of an mRNA-based combination vaccine candidate for COVID-19 and influenza.
(Source:https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-positive-topline-data-mrna )
Opportunities of the Influenza Vaccine Market
- Technological advancements in vaccine development are an opportunity for the market
The way vaccinations are made is being revolutionized by this change. with a switch from recombinant DNA technology and cell culture to conventional egg-based manufacturing. These developments offer not only quicker manufacturing times but maybe higher vaccination efficacy as well. The investment in the production of vaccines based on cells is one of the important data highlighting this trend. This change is essential because conventional egg-based vaccinations do not keep up with the rapid mutation of influenza viruses. The goal of novel, more recent vaccinations is to induce T-cell immunity, which lasts longer. Temperature-stable vaccines and nasal delivery-friendly formulations are examples of innovations that might be especially helpful in low- and middle-income nations.
• For instance, the Biomedical Advanced Research and Development Authority (BARDA) is funding research in this area, recently awarding $1.4 billion to develop a new generation of tools and technologies to protect against COVID-19.
(Source:https://www.hhs.gov/about/news/2023/08/22/funding-1-billion-vaccine-clinical-trials-326-million-new-monoclonal-antibody-100-million-explore-novel-vaccine-therapeuti-technologies.html )
• For instance, in August 2021, Seqirus invested in Next-generation influenza vaccine technology, self-amplifying mRNA. The company targeted the commencement of clinical trials for both seasonal and pandemic influenza vaccines.
(Source:https://www.ncbiotech.org/news/seqirus-search-next-generation-flu-vaccines )
We have various report editions of Influenza Vaccine Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.
Competitive Landscape: Influenza Vaccine Market
Major market participants who are essential in determining consumer preferences and market dynamics have a major impact on the influenza vaccine market. These major players provide consumers with easy access to a vast array of wardrobe options through their extensive retail networks and online platforms. Product adoption has increased as a result of their strong worldwide presence and well-known brand, which has also increased consumer trust and loyalty. In addition, these industry titans never stop funding R&D, bringing cutting-edge styles, materials, and practical features to clothing wardrobes to meet changing customer demands and preferences. These big players' combined efforts have a big impact on the market's future direction and level of competition.
Top Companies Market Share in Influenza Vaccine Industry: (In no particular order of Rank)
- Sanofi pasteur
- Novartis
- Abbott
- Pfizer
- CSL Limited
- Hualan Bio
- Changchun Bio
- Sinovac
- GSK
- CS Vaccine
- Tianyuan Bio
- Tiantan Bio
- Siobp
- Confidential Data
- Access The Paid Version
- Data Hidden
If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.
Which Region will dominate the Market in 2024?
North America is expected to hold a dominant market share in the forecast period. This is brought about by increased public knowledge of influenza illnesses and the available treatments, government education initiatives, and the development of new vaccinations made possible by technical developments. The existence of significant market players in the area and their substantial R&D spending are further factors contributing to the industry's growth. The influenza pandemic has become more often in North America, which has expanded the market. Seasonal influenza continues to cause significant death, disability, and economic disruption. It also contributes significantly to the worldwide clinical burden of lower respiratory tract infections. Canada wants to vaccinate 80% of individuals who are more likely to experience problems from the flu. This covers persons with chronic medical disorders who are 18–64 years old as well as seniors (65 years of age and older). Furthermore, by 2025, the Public Health Agency of Canada (PHAC) wants to have 80% of these population groups receive influenza vaccinations.
Which Region is Expanding at the Fastest CAGR?
Asia Pacific is anticipated to register the fastest growth rate throughout the forecast period as a result of healthcare reforms. The aging population, bettering healthcare systems, and the emergence of new competitors are further factors fueling the market's expansion. In July 2015, Hong Kong, China hosted the Global Influenza Initiative's (GII) fourth roundtable discussion. Gaining a deeper knowledge of the epidemiology, surveillance, immunization policies and programs, and barriers to influenza vaccination in the Asia-Pacific area was one of the meeting's goals. Furthermore, the high human density in the area contributes to a higher rate of transmission. The Singapore Ministry of Health reports that compared to other illnesses, respiratory infections like influenza are more common in the nation.
The current report Scope analyzes Influenza Vaccine Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com
- North America (United States, Canada, Mexico)
- Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
- Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
- South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
- Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)
Influenza Vaccine Market Share (%) by Region (2021-2033)
Influenza Vaccine Market Share (%) by Country
The above graph is for illustrative purposes only.
To learn more about geographical trends request the free sample pages.
Get Free Sample
Influenza Vaccine Market Analysis
Global Influenza Vaccine Market Report 2025 Edition talks about crucial market insights with the help of segments and sub-segments analysis. In this section, we reveal an in-depth analysis of the key factors influencing Influenza Vaccine Industry growth. Influenza Vaccine market has been segmented with the help of its Type, Valency Age Group, and others. Influenza Vaccine market analysis helps to understand key industry segments, and their global, regional, and country-level insights. Furthermore, this analysis also provides information pertaining to segments that are going to be most lucrative in the near future and their expected growth rate and future market opportunities. The report also provides detailed insights into factors responsible for the positive or negative growth of each industry segment.
Influenza Vaccine Market Type Segment Analysis
- Inactivated
- Live Attenuated
Inactivated vaccines held the largest market share of xx% in 2024 and are anticipated to grow at the fastest rate during the forecast period. The high prevalence of disease, the surge in demand for effective vaccines, and the presence of a large number of manufacturers are contributing to high segment share of the market. Viruses, bacteria, and other pathogens are cultivated in culture and subsequently destroyed to eliminate their ability to cause illness to create inactivated vaccines. Leading industry firms provide inactivated vaccinations with cutting-edge technology to prevent the illness. When administered to children aged 6-35 months, the inactivated vaccine elicited a good antibody response even a year after the first dose and subsequently decreased the risk of contracting influenza A and B. The CDC advises against writing up and preparing vaccinations until right before administering them. Syringes for general use are not meant to be stored; rather, they are meant to be used right away. Syringes containing pre-drawn vaccinations may become contaminated or harbor microorganisms, particularly if the vaccine is unpreserved.
Influenza Vaccine Market Share (%) by Type in 2021-2033
The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Influenza Vaccine Industry. Request a Free Sample PDF!
Influenza Vaccine Market Valency Segment Analysis
- Quadrivalent
- Trivalent
The quadrivalent segment is expected to hold a significant share of the influenza vaccine market due to its cost-effectiveness, efficacy against viral infections, and easy availability in hospitals and clinics. The World Health Organisation (WHO) mandated in 2012 that influenza B protection be added to the vaccination, increasing its effectiveness. As a result, the influenza vaccine with quadrivalent was released. The expansion of the market is also anticipated to be propelled by product approvals for the vaccination of the quadrivalent kind. Research from all across the world has demonstrated that the quadrivalent influenza vaccine works better in preventing influenza.
• For instance, in July 2022, the United States FDA approved the request of GlaxoSmithKline for the influenza vaccine, Fluarix, a quadrivalent vaccine. The Fluarix quadrivalent is a vaccine indicated for active immunization to prevent disease caused by the influenza A subtype virus and type B virus contained in the vaccine.
• For instance, After the United States started administering the Quadrivalent Influenza Vaccine, the number of influenza patients decreased by 1.3 million per year. The number of people being hospitalized was reduced by 12,472 and more than 663 lives were saved.
(Source:https://www.samitivejhospitals.com/article/detail/quadrivalent-influenza-vaccine )
Influenza Vaccine Market Share (%) by Valency in 2021-2033
2021
2025
2033
The above Graph is for representation purposes only. This chart does not depict actual Market share.
To learn more about market share request the free sample pages.
Get Free Sample
Influenza Vaccine Age Group Segment Analysis
The adult segment held the largest revenue share of xx% in 2024 owing to favorable efforts to increase immunization and high vaccine dose procurement by UNICEF, GAVI, and PAHO. Furthermore, the availability of immunization coverage sparked an increase in the number of older people receiving vaccinations. Adult immunization has also proven essential in reducing hospitalizations and influenza-related fatalities. Healthy adults who get inactivated parenteral influenza vaccine as opposed to not receiving any vaccination are likely to have influenza at a rate of less than 1% to slightly over 2%. Although the data was observational, the seasonal vaccination program during pregnancy did not appear to have a substantial impact on abortion or newborn mortality. It is advised that those who have a history of severe egg allergy that is, symptoms other than hives get the flu shot in a hospital environment under strict supervision.
(Source:https://www.cochrane.org/CD001269/ARI_vaccines-prevent-influenza-healthy-adults#:~:text=Inactivated%20influenza%20vaccines%20probably%20reduce,CI%200.75%20to%200.95%3B%2025%2C795 )
- Pediatric
- Adults
Influenza Vaccine Distribution Channel Segment Analysis
Hospitals & pharmacies captured the largest revenue share of xx% in 2024. A large quantity of vaccine supply from hospitals is anticipated to generate lucrative revenue opportunities for the segment. High flu and influenza incidences that result in increased hospital admissions are also anticipated to drive category demand. The American Pharmacists Association (APhA) started its immunization training program for pharmacists as early as 1996. Because of this, American chemists are now more widely acknowledged as authorities on vaccines. The need for flu shots delivered by pharmacists grew during the 2013–2014 flu season. The present Universal Influenza Immunisation Programme (UIIP) involves around 2000 pharmacies. By increasing immunization rates, chemists' administration of the flu vaccine has the potential to improve public health.
• For instance, In May 2021, during the pandemic, Australia launched a national flu vaccination program to reduce the population’s infection rate. As a result, seasonal vaccines are now available in Australia through community pharmacies and general practitioners.
(Source:https://www.health.gov.au/ministers/the-hon-greg-hunt-mp/media/national-flu-vaccination-program-officially-launches)
- Hospital & Retail Pharmacies
- Government Suppliers
- Other
Author's Detail
Anushka GoreResearch Associate at Cognitive Market Research
Anushka Gore is a seasoned market researcher specializing in the dynamic landscape of the Pharmaceutical industry. With a keen analytical mind and a deep passion for healthcare advancements, she has dedicated herself unraveling the intricate market trends and consumer behaviors that shape the future of medical technologies and services.
Bio :
Anushka Gore is a seasoned market researcher specializing in the dynamic landscape of the medical devices & consumables industry. She has dedicated herself unraveling the intricate market trends and consumer behaviors that shape the future of medical technologies and services. Her expertise in Market Research and business intelligence has equipped her with the skills necessary to analyze complex information and provide strategic recommendations.
In her current role, Anushka is a highly motivated and detail-oriented research analyst with a passion for uncovering valuable insights from data. She thrives in dynamic environments where her analytical abilities and research expertise can contribute to informed decision-making for businesses. Her collaborative approach facilitated effective communication of insights, fostering a data-driven culture within the organization.Anushka remains an invaluable asset in the dynamic landscape of market research.
Author's Conclusion
Influenza is one of the community-acquired respiratory infections that can cause significant morbidity in pediatric oncology patients, including hospitalization and secondary bacteremia. Adult immunization has also proven essential in reducing hospitalizations and influenza-related fatalities. Healthy adults who get inactivated parenteral influenza vaccine as opposed to not receiving any vaccination are likely to have influenza at a less. The expansion of the market is also anticipated to be propelled by product approvals for the vaccination of the quadrivalent kind. Major market participants who are essential in determining consumer preferences and market dynamics have a major impact on the influenza vaccine market.
Frequently Asked Questions
Influenza Vaccinemarket size and its growth rate has been provided in the report. The historical period included in the report is from 2021 to 2024, whereas, the report provides forecast data for the years 2025 to 2033. This will help you to in terms of global market share, regional market share, country level market share to understand how the market has been performing in the past and how it is going to perform in the following years. Correspondingly, historical and forecast analysis comprises sales and revenue data of the global Influenza Vaccinemarket. Market size for UK, Europe, North America, Asia Pacific, Middle East & Africa is also included in the report.
The major factors affecting the Influenza Vaccine market in a positive, as well as negative perspective, have been provided with detailed analysis in the report. This segment has encompassed drivers, opportunities, and challenges faced by the industry. This will help you to understand the major factors impacting Influenza Vaccine market trends and develop your business strategy accordingly.
Major manufacturers or list of Influenza Vaccine manufacturers 2024 involved in the market have been profiled in the report along with their business strategies, recent developments, SWOT analysis, business overview, and market Trend from the year 2021-2024. Influenza Vaccine Companies such as Sanofi pasteur, Novartis, Abbott, Pfizer, CSL Limited, Hualan Bio, Changchun Bio, Sinovac, GSK, CS Vaccine, Tianyuan Bio, Tiantan Bio, Siobp are part of the final deliverable document along with the same we can provide data for 2nd, 3rd, start-up level companies data and strategies as well. This will help you to understand the competitive analysis of the market and how other players are performing in the market. This detailed competitive analysis will help you to strategize your business accordingly and will keep you one step ahead. A quantitative and qualitative analysis of the main players in the Influenza Vaccine market is introduced, from the perspective of sales, revenue and price.
Under Influenza Vaccine market segments analysis Type, Valency, Age Group. It provides detailed insights on each type and application. Further, it provides which sub-segment is dominating the Influenza Vaccine market along with its reason. Additionally, the Influenza Vaccine market report will help you to analyze which sub-segment is fastest-growing during the forecast period.
After the analysis of the complete market, the report has provided how the COVID-19 pandemic has affected the market. All the parameters have covered the overall impact of COVID -19 on the market value, market trend & growth of the market, and how the major players in the particular market are adopting these changes. This will help you to understand the overall optimistic, pessimistic, and neutral effects of the coronavirus pandemic on the Influenza Vaccine market.
The Influenza Vaccine market has been analyzed thoroughly and has estimated the parameters which have affected the market in the historical period as well as how the market is going to perform in the following years. This will provide a complete market scenario and help you to strategize your next move accordingly to the Influenza Vaccine market Share.
The report gives an exhaustive investigation of the Influenza Vaccine market at country & regional levels, and provides an analysis of the industry trends in each of the regions, from sales, revenue, and consumption. It will help you to understand which region is dominating the market and is expected to grow significantly in the following years. The regional analysis will help you in strategizing the expansion of business.
Influenza Vaccinemarket report has provided PESTEL and Porter analysis to provide insightful information regarding the market scenario. It also provides market attractiveness analysis with an acknowledgment of various factors within the market, including growth rate and market size, as well as outside factors such as access to raw materials, competition, and industry capacity.
The sample report for the Influenza Vaccine Market can be obtained on demand from the website. Also, the 24*7 chat support & direct call services are provided to procure the sample report.
Please note, we have not disclose, all the sources consulted/referred during a market study due to confidentiality and paid service concern. However, rest assured that upon purchasing the service or paid report version, we will release the comprehensive list of sources along with the complete report and we also provide the data support where you can intract with the team of analysts who worked on the report.
Latest News about Influenza Vaccine Market
• In October 2023, BioNTech SE and Pfizer Inc. announced positive results from a Phase 1 study of mRNA-based combination vaccine for influenza and COVID-19.
• In May 2023, Novavax, Inc. announced positive results from a Phase 2 trial for three candidates: stand-alone influenza, COVID-19 combination, and high-dose COVID. These candidates showed robust immune responses, reassuring safety profiles, and reactogenicity comparable to authorized comparators, supporting their continued development.
(Source:https://ir.novavax.com/press-releases/2023-05-09-Positive-Phase-2-Topline-Results-Show-Novavaxs-COVID-Influenza-Combination%2C-Stand-alone-Influenza-and-High-dose-COVID-Vaccine-Candidates-Demonstrate-Robust-Immune-Responses )
• In August 2022, Vaxess Technologies Inc. announced the launch of a phase I trial for the H1 influenza vaccine delivered by Vaxess’s MIMIX patch.
(Source:https://www.vaxess.com/news-vaxess-announces-results-from-completion-of-mimix-flu-vaccine-patch-phase-1-trial#:~:text=Vaxess%20released%20its%20interim%2057,Results%20included%3A&text=Immune%20responses%3A%20The%20MIMIX%2DFlu,and%20broadly%20protective%20immune%20responses. )
• In July 2022, the U.S. Food and Drug Administration approved Fluzone- High-Dose Quadrivalent (Influenza Vaccine) and Flublok Quadrivalent (Influenza Vaccine) of Sanofi for the 2022-2023 influenza season. The product approval aimed to diversify its influenza product portfolio, thereby strengthening its market position.
• In May 2022, GSK plc announced that it had entered into a final agreement to acquire Affinivax, Inc., a clinical-stage biopharmaceutical business located in Cambridge, Boston, Massachusetts, for a USD 2.1 billion upfront payment and up to USD 1.2 billion in possible development milestones.
(Source:https://www.gsk.com/media/9847/fy-2022-results-announcement.pdf )
The FDA has authorized FluMist, a nasal spray vaccine that may be administered on oneself, in time for the upcoming influenza season. With this new approval, the nasal influenza vaccine becomes the first to be delivered without needing a healthcare provider for people aged 2 to 17. Adults ages 18 to 49 can self-administer the vaccine at home, and those ages 2 to 17 can have a caregiver administer it.
The first influenza vaccine to be approved for self- or caregiver administration offers a new means for people to get a seasonal influenza vaccination that is both safe and effective, maybe with more accessibility, flexibility, and convenience for families and individuals.
This approval shows the FDA's dedication to improving public health while providing an additional alternative for influenza immunization." Since 2003, FluMist has been authorized in the US, initially for people ages 5 to 49. The FDA extended permission to include people as young as two in 2007. The nasal vaccination is a live attenuated influenza shot sprayed into the nose. It contains weakened strains of live influenza viruses. This vaccination still needs to be prescribed, though.
Source Link: https://www.techtarget.com/pharmalifesciences/news/366611558/FDA-approves-self-administered-nasal-influenza-vaccine
Sources from Medical Devices & Consumables Industry
- http://www.trade.gov
- http://www.gov.uk
- http://www.fda.gov
- http://www.hhs.gov
- http://www.who.int
- http://www.bls.gov
- http://www.gao.gov
- http://www.ncbi.nlm.nih.gov
- http://www.healthcaredive.com
- http://www.weforum.org
- http://www.health.gov.za
- http://www.usaid.gov
- http://www.eumdr.com
- http://www.cdc.gov
- http://www.ama-assn.org
- http://www.washingtonpost.com
- http://www.ecfr.gov
- http://www.hbr.org
- http://www.worldbank.org
- http://www.commission.europa.eu
- http://www.cbi.eu
- http://www.unicef.org
- http://www.ecipe.org
- http://www.ema.europa.eu
Influenza Vaccine Market Report Table of Content
Disclaimer:
- This is just a redacted sample pages of the actual deliverable report and only for representative purposes
- Charts/Graphs/Numbers/data are only for Representative purposes and do not depict actual statistics.
- The table of Contents differs according to the user License selection. Current Displayed TOC is for the Corporate User License Report Edition. TOC Customization options: Add or Remove section/s Or chapter/s from the report.
- Specific Tables, Graphs, Sections, and Chapters can be ordered at a discounted price.
- If applicable; On Request Volume Data will also be provided (at an Additional Cost).
| Type | Inactivated, Live Attenuated |
| Valency | Quadrivalent, Trivalent |
| Age Group | Pediatric, Adults |
| Distribution Channel | Hospital & Retail Pharmacies, Government Suppliers, Other |
| List of Competitors | Sanofi pasteur, Novartis, Abbott, Pfizer, CSL Limited, Hualan Bio, Changchun Bio, Sinovac, GSK, CS Vaccine, Tianyuan Bio, Tiantan Bio, Siobp |
Expand All
This chapter will help you gain GLOBAL Market Analysis of Influenza Vaccine. Further deep in this chapter, you will be able to review Global Influenza Vaccine Market Split by various segments and Geographical Split.
Chapter 1 Global Market Analysis
-
1.1 Global Influenza Vaccine Revenue Market Size, Trend Analysis 2021 - 2033
-
1.2 Global Influenza Vaccine Market Size By Regions 2021 - 2033
Global Market has been segmented on the basis 5 major regions such as North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.
-
1.2.1 Global Influenza Vaccine Revenue Market Size By Region
-
-
1.3 Global Influenza Vaccine Market Size By Type 2021 - 2033
-
1.3.1 Inactivated Market Size
-
1.3.2 Live Attenuated Market Size
-
-
1.4 Global Influenza Vaccine Market Size By Valency 2021 - 2033
-
1.4.1 Quadrivalent Market Size
-
1.4.2 Trivalent Market Size
-
-
1.5 Global Influenza Vaccine Market Size By Age Group 2021 - 2033
-
1.5.1 Pediatric Market Size
-
1.5.2 Adults Market Size
-
-
1.6 Global Influenza Vaccine Market Size By Distribution Channel for 2021 - 2033
-
1.6.1 Hospital & Retail Pharmacies Market Size
-
1.6.2 Government Suppliers Market Size
-
1.6.3 Other Market Size
-
-
1.7 Global Level Competitor Analysis (Subject to Data Availability (Private Players))
-
1.8 Executive Summary Global Market (2021 vs 2025 vs 2033)
You can purchase only the Executive Summary of Global Market (2019 vs 2024 vs 2031)
-
1.8.1 Regional Market Revenue Summary 2021 vs 2025 vs 2033
-
1.8.2 Global Market Revenue Split By Type
-
1.8.3 Global Market Revenue Split By Valency
-
1.8.4 Global Market Revenue Split By Age Group
-
1.8.5 Global Market Revenue Split By Distribution Channel
-
1.8.6 Global Market Dynamics, Trends, Drivers, Restraints, Opportunities
Global Market Dynamics, Trends, Drivers, Restraints, Opportunities, Only Pointers will be deliverable
-
This chapter will help you gain North America Market Analysis of Influenza Vaccine. Further deep in this chapter, you will be able to review North America Influenza Vaccine Market Split by various segments and Country Split.
Chapter 2 North America Market Analysis
-
2.1 North America Influenza Vaccine Market Size 2021 - 2033
-
2.1.1 North America Influenza Vaccine Market Size By Country 2021 - 2033
-
2.1.2 North America Influenza Vaccine Market Size by Type 2021 - 2033
-
2.1.2.1 North America Inactivated Market Size
-
2.1.2.2 North America Live Attenuated Market Size
-
-
2.1.3 North America Influenza Vaccine Market Size by Valency 2021 - 2033
-
2.1.3.1 North America Quadrivalent Market Size
-
2.1.3.2 North America Trivalent Market Size
-
-
2.1.4 North America Influenza Vaccine Market Size by Age Group 2021 - 2033
-
2.1.4.1 North America Pediatric Market Size
-
2.1.4.2 North America Adults Market Size
-
-
2.1.5 North America Influenza Vaccine Market Size by Distribution Channel 2021 - 2033
-
2.1.5.1 North America Hospital & Retail Pharmacies Market Size
-
2.1.5.2 North America Government Suppliers Market Size
-
2.1.5.3 North America Other Market Size
-
-
-
2.2 United States Market Size 2021 - 2033
-
2.2.1 United States Influenza Vaccine Market Size by Type 2021 - 2033
-
2.2.2 United States Influenza Vaccine Market Size by Valency 2021 - 2033
-
2.2.3 United States Influenza Vaccine Market Size by Age Group 2021 - 2033
-
2.2.4 United States Influenza Vaccine Market Size by Distribution Channel 2021 - 2033
-
-
2.3 Canada Market Size 2021 - 2033
-
2.3.1 Canada Influenza Vaccine Market Size by Type 2021 - 2033
-
2.3.2 Canada Influenza Vaccine Market Size by Valency 2021 - 2033
-
2.3.3 Canada Influenza Vaccine Market Size by Age Group 2021 - 2033
-
2.3.4 Canada Influenza Vaccine Market Size by Distribution Channel 2021 - 2033
-
-
2.4 Mexico Market Size 2021 - 2033
-
2.4.1 Mexico Influenza Vaccine Market Size by Type 2021 - 2033
-
2.4.2 Mexico Influenza Vaccine Market Size by Valency 2021 - 2033
-
2.4.3 Mexico Influenza Vaccine Market Size by Age Group 2021 - 2033
-
2.4.4 Mexico Influenza Vaccine Market Size by Distribution Channel 2021 - 2033
-
This chapter will help you gain Europe Market Analysis of Influenza Vaccine. Further deep in this chapter, you will be able to review Europe Influenza Vaccine Market Split by various segments and Country Split.
Chapter 3 Europe Market Analysis
-
3.1 Europe Influenza Vaccine Market Size 2021 - 2033
-
3.1.1 Europe Influenza Vaccine Market Size By Country 2021 - 2033
-
3.1.2 Europe Influenza Vaccine Market Size by Type 2021 - 2033
-
3.1.2.1 Europe Inactivated Market Size
-
3.1.2.2 Europe Live Attenuated Market Size
-
-
3.1.3 Europe Influenza Vaccine Market Size by Valency 2021 - 2033
-
3.1.3.1 Europe Quadrivalent Market Size
-
3.1.3.2 Europe Trivalent Market Size
-
-
3.1.4 Europe Influenza Vaccine Market Size by Age Group 2021 - 2033
-
3.1.4.1 Europe Pediatric Market Size
-
3.1.4.2 Europe Adults Market Size
-
-
3.1.5 Europe Influenza Vaccine Market Size by Distribution Channel 2021 - 2033
-
3.1.5.1 Europe Hospital & Retail Pharmacies Market Size
-
3.1.5.2 Europe Government Suppliers Market Size
-
3.1.5.3 Europe Other Market Size
-
-
-
3.2 United Kingdom Market Size 2021 - 2033
-
3.2.1 United Kingdom Influenza Vaccine Market Size by Type 2021 - 2033
-
3.2.2 United Kingdom Influenza Vaccine Market Size by Valency 2021 - 2033
-
3.2.3 United Kingdom Influenza Vaccine Market Size by Age Group 2021 - 2033
-
3.2.4 United Kingdom Influenza Vaccine Market Size by Distribution Channel 2021 - 2033
-
-
3.3 France Market Size 2021 - 2033
-
3.3.1 France Influenza Vaccine Market Size by Type 2021 - 2033
-
3.3.2 France Influenza Vaccine Market Size by Valency 2021 - 2033
-
3.3.3 France Influenza Vaccine Market Size by Age Group 2021 - 2033
-
3.3.4 France Influenza Vaccine Market Size by Distribution Channel 2021 - 2033
-
-
3.4 Germany Market Size 2021 - 2033
-
3.4.1 Germany Influenza Vaccine Market Size by Type 2021 - 2033
-
3.4.2 Germany Influenza Vaccine Market Size by Valency 2021 - 2033
-
3.4.3 Germany Influenza Vaccine Market Size by Age Group 2021 - 2033
-
3.4.4 Germany Influenza Vaccine Market Size by Distribution Channel 2021 - 2033
-
-
3.5 Italy Market Size 2021 - 2033
-
3.5.1 Italy Influenza Vaccine Market Size by Type 2021 - 2033
-
3.5.2 Italy Influenza Vaccine Market Size by Valency 2021 - 2033
-
3.5.3 Italy Influenza Vaccine Market Size by Age Group 2021 - 2033
-
3.5.4 Italy Influenza Vaccine Market Size by Distribution Channel 2021 - 2033
-
-
3.6 Russia Market Size 2021 - 2033
-
3.6.1 Russia Influenza Vaccine Market Size by Type 2021 - 2033
-
3.6.2 Russia Influenza Vaccine Market Size by Valency 2021 - 2033
-
3.6.3 Russia Influenza Vaccine Market Size by Age Group 2021 - 2033
-
3.6.4 Russia Influenza Vaccine Market Size by Distribution Channel 2021 - 2033
-
-
3.7 Spain Market Size 2021 - 2033
-
3.7.1 Spain Influenza Vaccine Market Size by Type 2021 - 2033
-
3.7.2 Spain Influenza Vaccine Market Size by Valency 2021 - 2033
-
3.7.3 Spain Influenza Vaccine Market Size by Age Group 2021 - 2033
-
3.7.4 Spain Influenza Vaccine Market Size by Distribution Channel 2021 - 2033
-
-
3.8 Sweden Market Size 2021 - 2033
-
3.8.1 Sweden Influenza Vaccine Market Size by Type 2021 - 2033
-
3.8.2 Sweden Influenza Vaccine Market Size by Valency 2021 - 2033
-
3.8.3 Sweden Influenza Vaccine Market Size by Age Group 2021 - 2033
-
3.8.4 Sweden Influenza Vaccine Market Size by Distribution Channel 2021 - 2033
-
-
3.9 Denmark Market Size 2021 - 2033
-
3.9.1 Denmark Influenza Vaccine Market Size by Type 2021 - 2033
-
3.9.2 Denmark Influenza Vaccine Market Size by Valency 2021 - 2033
-
3.9.3 Denmark Influenza Vaccine Market Size by Age Group 2021 - 2033
-
3.9.4 Denmark Influenza Vaccine Market Size by Distribution Channel 2021 - 2033
-
-
3.10 Switzerland Market Size 2021 - 2033
-
3.10.1 Switzerland Influenza Vaccine Market Size by Type 2021 - 2033
-
3.10.2 Switzerland Influenza Vaccine Market Size by Valency 2021 - 2033
-
3.10.3 Switzerland Influenza Vaccine Market Size by Age Group 2021 - 2033
-
3.10.4 Switzerland Influenza Vaccine Market Size by Distribution Channel 2021 - 2033
-
-
3.11 Luxembourg Market Size 2021 - 2033
-
3.11.1 Luxembourg Influenza Vaccine Market Size by Type 2021 - 2033
-
3.11.2 Luxembourg Influenza Vaccine Market Size by Valency 2021 - 2033
-
3.11.3 Luxembourg Influenza Vaccine Market Size by Age Group 2021 - 2033
-
3.11.4 Luxembourg Influenza Vaccine Market Size by Distribution Channel 2021 - 2033
-
-
3.12 Rest of Europe Market Size 2021 - 2033
-
3.12.1 Rest of Europe Influenza Vaccine Market Size by Type 2021 - 2033
-
3.12.2 Rest of Europe Influenza Vaccine Market Size by Valency 2021 - 2033
-
3.12.3 Rest of Europe Influenza Vaccine Market Size by Age Group 2021 - 2033
-
3.12.4 Rest of Europe Influenza Vaccine Market Size by Distribution Channel 2021 - 2033
-
This chapter will help you gain Asia Pacific Market Analysis of Influenza Vaccine. Further deep in this chapter, you will be able to review Asia Pacific Influenza Vaccine Market Split by various segments and Country Split.
Chapter 4 Asia Pacific Market Analysis
-
4.1 Asia Pacific Influenza Vaccine Market Size 2021 - 2033
-
4.1.1 Asia Pacific Influenza Vaccine Market Size By Country 2021 - 2033
-
4.1.2 Asia Pacific Influenza Vaccine Market Size by Type 2021 - 2033
-
4.1.2.1 Asia Pacific Inactivated Market Size
-
4.1.2.2 Asia Pacific Live Attenuated Market Size
-
-
4.1.3 Asia Pacific Influenza Vaccine Market Size by Valency 2021 - 2033
-
4.1.3.1 Asia Pacific Quadrivalent Market Size
-
4.1.3.2 Asia Pacific Trivalent Market Size
-
-
4.1.4 Asia Pacific Influenza Vaccine Market Size by Age Group 2021 - 2033
-
4.1.4.1 Asia Pacific Pediatric Market Size
-
4.1.4.2 Asia Pacific Adults Market Size
-
-
4.1.5 Asia Pacific Influenza Vaccine Market Size by Distribution Channel 2021 - 2033
-
4.1.5.1 Asia Pacific Hospital & Retail Pharmacies Market Size
-
4.1.5.2 Asia Pacific Government Suppliers Market Size
-
4.1.5.3 Asia Pacific Other Market Size
-
-
-
4.2 China Influenza Vaccine Market Size 2021 - 2033
-
4.2.1 China Influenza Vaccine Market Size by Type 2021 - 2033
-
4.2.2 China Influenza Vaccine Market Size by Valency 2021 - 2033
-
4.2.3 China Influenza Vaccine Market Size by Age Group 2021 - 2033
-
4.2.4 China Influenza Vaccine Market Size by Distribution Channel 2021 - 2033
-
-
4.3 Japan Influenza Vaccine Market Size 2021 - 2033
-
4.3.1 Japan Influenza Vaccine Market Size by Type 2021 - 2033
-
4.3.2 Japan Influenza Vaccine Market Size by Valency 2021 - 2033
-
4.3.3 Japan Influenza Vaccine Market Size by Age Group 2021 - 2033
-
4.3.4 Japan Influenza Vaccine Market Size by Distribution Channel 2021 - 2033
-
-
4.4 South Korea Influenza Vaccine Market Size 2021 - 2033
-
4.4.1 South Korea Influenza Vaccine Market Size by Type 2021 - 2033
-
4.4.2 South Korea Influenza Vaccine Market Size by Valency 2021 - 2033
-
4.4.3 South Korea Influenza Vaccine Market Size by Age Group 2021 - 2033
-
4.4.4 South Korea Influenza Vaccine Market Size by Distribution Channel 2021 - 2033
-
-
4.5 India Influenza Vaccine Market Size 2021 - 2033
-
4.5.1 India Influenza Vaccine Market Size by Type 2021 - 2033
-
4.5.2 India Influenza Vaccine Market Size by Valency 2021 - 2033
-
4.5.3 India Influenza Vaccine Market Size by Age Group 2021 - 2033
-
4.5.4 India Influenza Vaccine Market Size by Distribution Channel 2021 - 2033
-
-
4.6 Australia Influenza Vaccine Market Size 2021 - 2033
-
4.6.1 Australia Influenza Vaccine Market Size by Type 2021 - 2033
-
4.6.2 Australia Influenza Vaccine Market Size by Valency 2021 - 2033
-
4.6.3 Australia Influenza Vaccine Market Size by Age Group 2021 - 2033
-
4.6.4 Australia Influenza Vaccine Market Size by Distribution Channel 2021 - 2033
-
-
4.7 Singapore Influenza Vaccine Market Size 2021 - 2033
-
4.7.1 Singapore Influenza Vaccine Market Size by Type 2021 - 2033
-
4.7.2 Singapore Influenza Vaccine Market Size by Valency 2021 - 2033
-
4.7.3 Singapore Influenza Vaccine Market Size by Age Group 2021 - 2033
-
4.7.4 Singapore Influenza Vaccine Market Size by Distribution Channel 2021 - 2033
-
-
4.8 Taiwan Influenza Vaccine Market Size 2021 - 2033
-
4.8.1 Taiwan Influenza Vaccine Market Size by Type 2021 - 2033
-
4.8.2 Taiwan Influenza Vaccine Market Size by Valency 2021 - 2033
-
4.8.3 Taiwan Influenza Vaccine Market Size by Age Group 2021 - 2033
-
4.8.4 Taiwan Influenza Vaccine Market Size by Distribution Channel 2021 - 2033
-
-
4.9 South East Asia Influenza Vaccine Market Size 2021 - 2033
-
4.9.1 South East Asia Influenza Vaccine Market Size by Type 2021 - 2033
-
4.9.2 South East Asia Influenza Vaccine Market Size by Valency 2021 - 2033
-
4.9.3 South East Asia Influenza Vaccine Market Size by Age Group 2021 - 2033
-
4.9.4 South East Asia Influenza Vaccine Market Size by Distribution Channel 2021 - 2033
-
-
4.10 Rest of APAC Influenza Vaccine Market Size 2021 - 2033
-
4.10.1 Rest of APAC Influenza Vaccine Market Size by Type 2021 - 2033
-
4.10.2 Rest of APAC Influenza Vaccine Market Size by Valency 2021 - 2033
-
4.10.3 Rest of APAC Influenza Vaccine Market Size by Age Group 2021 - 2033
-
4.10.4 Rest of APAC Influenza Vaccine Market Size by Distribution Channel 2021 - 2033
-
This chapter will help you gain South America Market Analysis of Influenza Vaccine. Further deep in this chapter, you will be able to review South America Influenza Vaccine Market Split by various segments and Country Split.
Chapter 5 South America Market Analysis
-
5.1 South America Influenza Vaccine Market Size 2021 - 2033
-
5.1.1 South America Influenza Vaccine Market Size By Country 2021 - 2033
-
5.1.2 South America Influenza Vaccine Market Size by Type 2021 - 2033
-
5.1.2.1 South America Inactivated Market Size
-
5.1.2.2 South America Live Attenuated Market Size
-
-
5.1.3 South America Influenza Vaccine Market Size by Valency 2021 - 2033
-
5.1.3.1 South America Quadrivalent Market Size
-
5.1.3.2 South America Trivalent Market Size
-
-
5.1.4 South America Influenza Vaccine Market Size by Age Group 2021 - 2033
-
5.1.4.1 South America Pediatric Market Size
-
5.1.4.2 South America Adults Market Size
-
-
5.1.5 South America Influenza Vaccine Market Size by Distribution Channel 2021 - 2033
-
5.1.5.1 South America Hospital & Retail Pharmacies Market Size
-
5.1.5.2 South America Government Suppliers Market Size
-
5.1.5.3 South America Other Market Size
-
-
-
5.2 Brazil Influenza Vaccine Market Size 2021 - 2033
-
5.2.1 Brazil Influenza Vaccine Market Size by Type 2021 - 2033
-
5.2.2 Brazil Influenza Vaccine Market Size by Valency 2021 - 2033
-
5.2.3 Brazil Influenza Vaccine Market Size by Age Group 2021 - 2033
-
5.2.4 Brazil Influenza Vaccine Market Size by Distribution Channel 2021 - 2033
-
-
5.3 Argentina Influenza Vaccine Market Size 2021 - 2033
-
5.3.1 Argentina Influenza Vaccine Market Size by Type 2021 - 2033
-
5.3.2 Argentina Influenza Vaccine Market Size by Valency 2021 - 2033
-
5.3.3 Argentina Influenza Vaccine Market Size by Age Group 2021 - 2033
-
5.3.4 Argentina Influenza Vaccine Market Size by Distribution Channel 2021 - 2033
-
-
5.4 Colombia Influenza Vaccine Market Size 2021 - 2033
-
5.4.1 Colombia Influenza Vaccine Market Size by Type 2021 - 2033
-
5.4.2 Colombia Influenza Vaccine Market Size by Valency 2021 - 2033
-
5.4.3 Colombia Influenza Vaccine Market Size by Age Group 2021 - 2033
-
5.4.4 Colombia Influenza Vaccine Market Size by Distribution Channel 2021 - 2033
-
-
5.5 Peru Influenza Vaccine Market Size 2021 - 2033
-
5.5.1 Peru Influenza Vaccine Market Size by Type 2021 - 2033
-
5.5.2 Peru Influenza Vaccine Market Size by Valency 2021 - 2033
-
5.5.3 Peru Influenza Vaccine Market Size by Age Group 2021 - 2033
-
5.5.4 Peru Influenza Vaccine Market Size by Distribution Channel 2021 - 2033
-
-
5.6 Chile Influenza Vaccine Market Size 2021 - 2033
-
5.6.1 Chile Influenza Vaccine Market Size by Type 2021 - 2033
-
5.6.2 Chile Influenza Vaccine Market Size by Valency 2021 - 2033
-
5.6.3 Chile Influenza Vaccine Market Size by Age Group 2021 - 2033
-
5.6.4 Chile Influenza Vaccine Market Size by Distribution Channel 2021 - 2033
-
-
5.7 Rest of South America Influenza Vaccine Market Size 2021 - 2033
-
5.7.1 Rest of South America Influenza Vaccine Market Size by Type 2021 - 2033
-
5.7.2 Rest of South America Influenza Vaccine Market Size by Valency 2021 - 2033
-
5.7.3 Rest of South America Influenza Vaccine Market Size by Age Group 2021 - 2033
-
5.7.4 Rest of South America Influenza Vaccine Market Size by Distribution Channel 2021 - 2033
-
This chapter will help you gain Middle East Market Analysis of Influenza Vaccine. Further deep in this chapter, you will be able to review Middle East Influenza Vaccine Market Split by various segments and Country Split.
Chapter 6 Middle East Market Analysis
-
6.1 Middle East Influenza Vaccine Market Size 2021 - 2033
-
6.1.1 Middle East Influenza Vaccine Market Size By Country 2021 - 2033
-
6.1.2 Middle East Influenza Vaccine Market Size by Type 2021 - 2033
-
6.1.2.1 Middle East Inactivated Market Size
-
6.1.2.2 Middle East Live Attenuated Market Size
-
-
6.1.3 Middle East Influenza Vaccine Market Size by Valency 2021 - 2033
-
6.1.3.1 Middle East Quadrivalent Market Size
-
6.1.3.2 Middle East Trivalent Market Size
-
-
6.1.4 Middle East Influenza Vaccine Market Size by Age Group 2021 - 2033
-
6.1.4.1 Middle East Pediatric Market Size
-
6.1.4.2 Middle East Adults Market Size
-
-
6.1.5 Middle East Influenza Vaccine Market Size by Distribution Channel 2021 - 2033
-
6.1.5.1 Middle East Hospital & Retail Pharmacies Market Size
-
6.1.5.2 Middle East Government Suppliers Market Size
-
6.1.5.3 Middle East Other Market Size
-
-
-
6.2 Saudi Arabia Influenza Vaccine Market Size 2021 - 2033
-
6.2.1 Saudi Arabia Influenza Vaccine Market Size by Type 2021 - 2033
-
6.2.2 Saudi Arabia Influenza Vaccine Market Size by Valency 2021 - 2033
-
6.2.3 Saudi Arabia Influenza Vaccine Market Size by Age Group 2021 - 2033
-
6.2.4 Saudi Arabia Influenza Vaccine Market Size by Distribution Channel 2021 - 2033
-
-
6.3 Turkey Influenza Vaccine Market Size 2021 - 2033
-
6.3.1 Turkey Influenza Vaccine Market Size by Type 2021 - 2033
-
6.3.2 Turkey Influenza Vaccine Market Size by Valency 2021 - 2033
-
6.3.3 Turkey Influenza Vaccine Market Size by Age Group 2021 - 2033
-
6.3.4 Turkey Influenza Vaccine Market Size by Distribution Channel 2021 - 2033
-
-
6.4 UAE Influenza Vaccine Market Size 2021 - 2033
-
6.4.1 UAE Influenza Vaccine Market Size by Type 2021 - 2033
-
6.4.2 UAE Influenza Vaccine Market Size by Valency 2021 - 2033
-
6.4.3 UAE Influenza Vaccine Market Size by Age Group 2021 - 2033
-
6.4.4 UAE Influenza Vaccine Market Size by Distribution Channel 2021 - 2033
-
-
6.5 Egypt Influenza Vaccine Market Size 2021 - 2033
-
6.5.1 Egypt Influenza Vaccine Market Size by Type 2021 - 2033
-
6.5.2 Egypt Influenza Vaccine Market Size by Valency 2021 - 2033
-
6.5.3 Egypt Influenza Vaccine Market Size by Age Group 2021 - 2033
-
6.5.4 Egypt Influenza Vaccine Market Size by Distribution Channel 2021 - 2033
-
-
6.6 Qatar Influenza Vaccine Market Size 2021 - 2033
-
6.6.1 Qatar Influenza Vaccine Market Size by Type 2021 - 2033
-
6.6.2 Qatar Influenza Vaccine Market Size by Valency 2021 - 2033
-
6.6.3 Qatar Influenza Vaccine Market Size by Age Group 2021 - 2033
-
6.6.4 Qatar Influenza Vaccine Market Size by Distribution Channel 2021 - 2033
-
-
6.7 Rest of Middle East Influenza Vaccine Market Size 2021 - 2033
-
6.7.1 Rest of Middle East Influenza Vaccine Market Size by Type 2021 - 2033
-
6.7.2 Rest of Middle East Influenza Vaccine Market Size by Valency 2021 - 2033
-
6.7.3 Rest of Middle East Influenza Vaccine Market Size by Age Group 2021 - 2033
-
6.7.4 Rest of Middle East Influenza Vaccine Market Size by Distribution Channel 2021 - 2033
-
This chapter will help you gain Middle East Market Analysis of Influenza Vaccine. Further deep in this chapter, you will be able to review Middle East Influenza Vaccine Market Split by various segments and Country Split.
Chapter 7 Africa Market Analysis
-
7.1 Africa Influenza Vaccine Market Size 2021 - 2033
-
7.1.1 Africa Influenza Vaccine Market Size By Country 2021 - 2033
-
7.1.2 Africa Influenza Vaccine Market Size by Type 2021 - 2033
-
7.1.2.1 Africa Inactivated Market Size
-
7.1.2.2 Africa Live Attenuated Market Size
-
-
7.1.3 Africa Influenza Vaccine Market Size by Valency 2021 - 2033
-
7.1.3.1 Africa Quadrivalent Market Size
-
7.1.3.2 Africa Trivalent Market Size
-
-
7.1.4 Africa Influenza Vaccine Market Size by Age Group 2021 - 2033
-
7.1.4.1 Africa Pediatric Market Size
-
7.1.4.2 Africa Adults Market Size
-
-
7.1.5 Africa Influenza Vaccine Market Size by Distribution Channel 2021 - 2033
-
7.1.5.1 Africa Hospital & Retail Pharmacies Market Size
-
7.1.5.2 Africa Government Suppliers Market Size
-
7.1.5.3 Africa Other Market Size
-
-
-
7.2 Nigeria Influenza Vaccine Market Size 2021 - 2033
-
7.2.1 Nigeria Influenza Vaccine Market Size by Type 2021 - 2033
-
7.2.2 Nigeria Influenza Vaccine Market Size by Valency 2021 - 2033
-
7.2.3 Nigeria Influenza Vaccine Market Size by Age Group 2021 - 2033
-
7.2.4 Nigeria Influenza Vaccine Market Size by Distribution Channel 2021 - 2033
-
-
7.3 South Africa Influenza Vaccine Market Size 2021 - 2033
-
7.3.1 South Africa Influenza Vaccine Market Size by Type 2021 - 2033
-
7.3.2 South Africa Influenza Vaccine Market Size by Valency 2021 - 2033
-
7.3.3 South Africa Influenza Vaccine Market Size by Age Group 2021 - 2033
-
7.3.4 South Africa Influenza Vaccine Market Size by Distribution Channel 2021 - 2033
-
-
7.4 Rest of Africa Influenza Vaccine Market Size 2021 - 2033
-
7.4.1 Rest of Africa Influenza Vaccine Market Size by Type 2021 - 2033
-
7.4.2 Rest of Africa Influenza Vaccine Market Size by Valency 2021 - 2033
-
7.4.3 Rest of Africa Influenza Vaccine Market Size by Age Group 2021 - 2033
-
7.4.4 Rest of Africa Influenza Vaccine Market Size by Distribution Channel 2021 - 2033
-
This chapter provides an in-depth analysis of the market share among key competitors of Influenza Vaccine. The analysis highlights each competitor's position in the market, growth trends, and financial performance, offering insights into competitive dynamics, and emerging players.
Chapter 8 Competitor Analysis (Subject to Data Availability (Private Players))
-
8.1 Top Competitors Analysis
-
8.1.1 Top Players Ranking 2024
-
8.1.2 Global Influenza Vaccine Market Revenue and Share by Key Players
(Subject to Data Availability (Private Players))
-
8.1.3 Industry Mergers and Acquisition Analysis
-
8.1.4 New Product Launch Analysis
-
-
8.2 Company Profile (Data Subject to Availability) Sample Format
-
8.2.1 Sanofi pasteur
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.1.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.1.2 Business Overview
-
8.2.1.3 Financials (Subject to data availability)
-
8.2.1.4 Product Types Specification
-
8.2.1.5 Business Strategy
-
8.2.1.6 S.W.O.TAnalysis
-
-
8.2.2 Novartis
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.2.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.2.2 Business Overview
-
8.2.2.3 Financials (Subject to data availability)
-
8.2.2.4 Product Types Specification
-
8.2.2.5 Business Strategy
-
8.2.2.6 S.W.O.TAnalysis
-
-
8.2.3 Abbott
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.3.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.3.2 Business Overview
-
8.2.3.3 Financials (Subject to data availability)
-
8.2.3.4 Product Types Specification
-
8.2.3.5 Business Strategy
-
8.2.3.6 S.W.O.TAnalysis
-
-
8.2.4 Pfizer
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.4.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.4.2 Business Overview
-
8.2.4.3 Financials (Subject to data availability)
-
8.2.4.4 Product Types Specification
-
8.2.4.5 Business Strategy
-
8.2.4.6 S.W.O.TAnalysis
-
-
8.2.5 CSL Limited
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.5.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.5.2 Business Overview
-
8.2.5.3 Financials (Subject to data availability)
-
8.2.5.4 Product Types Specification
-
8.2.5.5 Business Strategy
-
8.2.5.6 S.W.O.TAnalysis
-
-
8.2.6 Hualan Bio
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.6.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.6.2 Business Overview
-
8.2.6.3 Financials (Subject to data availability)
-
8.2.6.4 Product Types Specification
-
8.2.6.5 Business Strategy
-
8.2.6.6 S.W.O.TAnalysis
-
-
8.2.7 Changchun Bio
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.7.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.7.2 Business Overview
-
8.2.7.3 Financials (Subject to data availability)
-
8.2.7.4 Product Types Specification
-
8.2.7.5 Business Strategy
-
8.2.7.6 S.W.O.TAnalysis
-
-
8.2.8 Sinovac
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.8.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.8.2 Business Overview
-
8.2.8.3 Financials (Subject to data availability)
-
8.2.8.4 Product Types Specification
-
8.2.8.5 Business Strategy
-
8.2.8.6 S.W.O.TAnalysis
-
-
8.2.9 GSK
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.9.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.9.2 Business Overview
-
8.2.9.3 Financials (Subject to data availability)
-
8.2.9.4 Product Types Specification
-
8.2.9.5 Business Strategy
-
8.2.9.6 S.W.O.TAnalysis
-
-
8.2.10 CS Vaccine
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.10.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.10.2 Business Overview
-
8.2.10.3 Financials (Subject to data availability)
-
8.2.10.4 Product Types Specification
-
8.2.10.5 Business Strategy
-
8.2.10.6 S.W.O.TAnalysis
-
-
8.2.11 Tianyuan Bio
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.11.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.11.2 Business Overview
-
8.2.11.3 Financials (Subject to data availability)
-
8.2.11.4 Product Types Specification
-
8.2.11.5 Business Strategy
-
8.2.11.6 S.W.O.TAnalysis
-
-
8.2.12 Tiantan Bio
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.12.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.12.2 Business Overview
-
8.2.12.3 Financials (Subject to data availability)
-
8.2.12.4 Product Types Specification
-
8.2.12.5 Business Strategy
-
8.2.12.6 S.W.O.TAnalysis
-
-
8.2.13 Siobp
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.13.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.13.2 Business Overview
-
8.2.13.3 Financials (Subject to data availability)
-
8.2.13.4 Product Types Specification
-
8.2.13.5 Business Strategy
-
8.2.13.6 S.W.O.TAnalysis
-
-
This chapter would comprehensively cover market drivers, trends, restraints, opportunities, and various in-depth analyses like industrial chain, PESTEL, Porter’s Five Forces, and ESG, among others. It would also include product life cycle, technological advancements, and patent insights.
Chapter 9 Qualitative Analysis (Subject to Data Availability)
-
9.1 Market Drivers
-
9.2 Market Restraints
-
9.3 Market Trends
-
9.4 Market Opportunity
-
9.5 Technological Road Map (Subject to Data Availability)
-
9.6 Product Life Cycle (Subject to Data Availability)
-
9.7 Consumer Preference Analysis
-
9.8 Market Attractiveness Analysis
-
9.9 PESTEL Analysis
-
9.9.1 Political Factors
-
9.9.2 Economic Factors
-
9.9.3 Social Factors
-
9.9.4 Technological Factors
-
9.9.5 Legal Factors
-
9.9.6 Environmental Factors
-
-
9.10 Industrial Chain Analysis (Subject to Data Availability)
-
9.10.1 Industry Chain Analysis
-
9.10.2 Manufacturing Cost Analysis
-
9.10.3 Supply Side Analysis
-
9.10.3.1 Raw Material Analysis
-
9.10.3.2 Raw Material Procurement Analysis
-
9.10.3.3 Raw Material Price Trend Analysis
-
-
-
9.11 Porter’s Five Forces Analysis
-
9.11.1 Bargaining Power of Suppliers
-
9.11.2 Bargaining Power of Buyers
-
9.11.3 Threat of New Entrants
-
9.11.4 Threat of Substitutes
-
9.11.5 Degree of Competition
-
-
9.12 Patent Analysis (Subject to Data Availability)
-
9.13 ESG Analysis
Segmentation Type Analysis 2019 -2031, will provide market size split by Type. This Information is provided at Global Level, Regional Level and Top Countries Level The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 10 Market Split by Type Analysis 2021 - 2033
-
10.1 Inactivated
-
10.1.1 Global Influenza Vaccine Revenue Market Size and Share by Inactivated 2021 - 2033
-
-
10.2 Live Attenuated
-
10.2.1 Global Influenza Vaccine Revenue Market Size and Share by Live Attenuated 2021 - 2033
-
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 11 Market Split by Valency Analysis 2021 - 2033
-
11.1 Quadrivalent
-
11.1.1 Global Influenza Vaccine Revenue Market Size and Share by Quadrivalent 2021 - 2033
-
-
11.2 Trivalent
-
11.2.1 Global Influenza Vaccine Revenue Market Size and Share by Trivalent 2021 - 2033
-
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 12 Market Split by Age Group Analysis 2021 - 2033
-
12.1 Pediatric
-
12.1.1 Global Influenza Vaccine Revenue Market Size and Share by Pediatric 2021 - 2033
-
-
12.2 Adults
-
12.2.1 Global Influenza Vaccine Revenue Market Size and Share by Adults 2021 - 2033
-
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 13 Market Split by Distribution Channel Analysis 2021 - 2033
-
13.1 Hospital & Retail Pharmacies
-
13.1.1 Global Influenza Vaccine Revenue Market Size and Share by Hospital & Retail Pharmacies 2021 - 2033
-
-
13.2 Government Suppliers
-
13.2.1 Global Influenza Vaccine Revenue Market Size and Share by Government Suppliers 2021 - 2033
-
-
13.3 Other
-
13.3.1 Global Influenza Vaccine Revenue Market Size and Share by Other 2021 - 2033
-
This chapter helps you understand the Key Takeaways and Analyst Point of View of the global Influenza Vaccine market
Chapter 14 Research Findings
-
14.1 Key Takeaways
-
14.2 Analyst Point of View
Here the analyst will summarize the content of entire report and will share his view point on the current industry scenario and how the market is expected to perform in the near future. The points shared by the analyst are based on his/her detailed in-depth understanding of the market during the course of this report study. You will be provided exclusive rights to interact with the concerned analyst for unlimited time pre purchase as well as post purchase of the report.
-
14.3 Assumptions and Acronyms
Chapter 15 Research Methodology and Sources
-
15.1 Primary Data Collection
-
15.1.1 Steps for Primary Data Collection
-
15.1.1.1 Identification of KOL
-
-
15.1.2 Backward Integration
-
15.1.3 Forward Integration
-
15.1.4 How Primary Research Help Us
-
15.1.5 Modes of Primary Research
-
-
15.2 Secondary Research
-
15.2.1 How Secondary Research Help Us
-
15.2.2 Sources of Secondary Research
-
-
15.3 Data Validation
-
15.3.1 Data Triangulation
-
15.3.2 Top Down & Bottom Up Approach
-
15.3.3 Cross check KOL Responses with Secondary Data
-
-
15.4 Data Representation
Sample Format of Deliverables
The Tables, Graphs/Charts are only for representative purposes and do not depict actual statistics. Purchase full Report access to actual data.
Qualitative Analysis
Market Timeline 2021 till 2033, Market Size, Revenue/Volume Share, Forecast and CAGR, Competitor Analysis, Regional Analysis, Country Analysis, Segment Analysis, Market Trends, Drivers, Opportunities, Restraints, ESG Analysis, Porters Analysis, PESTEL Analysis, Market Attractiveness, Patent Analysis, Technological Trend, SWOT Analysis, COVID-19 Analysis, Consumer Behavior Analysis, etc.
Market Timeline 2021 till 2033, Market Size, Revenue/Volume Share, Forecast and CAGR, Competitor Analysis, Regional Analysis, Country Analysis, Segment Analysis, Market Trends, Drivers, Opportunities, Restraints, ESG Analysis, Porters Analysis, PESTEL Analysis, Market Attractiveness, Patent Analysis, Technological Trend, SWOT Analysis, COVID-19 Analysis, Consumer Behavior Analysis, etc.
Research Methodology Implemented by Anushka Gore and Team
- 1 Data Gathering
- 1.1 Primary Research
- 1.1.1 Steps for Primary Data Collection
- 1.1.1.1 Identification of KOL
- 1.1.1.2 Backward Integration
- 1.1.1.3 Forward Integration
- 1.1.1.4 How Primary Research Help Us
- 1.1.1.5 Modes of Primary Research
- 1.1.1 Steps for Primary Data Collection
- 1.2 Secondary Research
- 1.2.1 How Secondary Research Help Us
- 1.2.2 Sources of Secondary Research
- 1.1 Primary Research
- 2 Data Validation
- 2.1 Cross check KOL Responses with Secondary Data
- 2.2 Top Down & Bottom Up Approach
- 2.3 Data Triangulation
- 3 Data Representation
Key Questions Answered By Influenza Vaccine Market Report 2025
| Why Inactivated have a significant impact on Influenza Vaccine market? |
| What are the key factors affecting the Inactivated and Live Attenuated of Influenza Vaccine Market? |
| What is the CAGR/Growth Rate of Quadrivalent during the forecast period? |
| By type, which segment accounted for largest share of the global Influenza Vaccine Market? |
| Which region is expected to dominate the global Influenza Vaccine Market within the forecast period? |
| Segmentation Level Customization |
|
| Global level Data Customization |
|
| Region level Data Customization |
|
| Country level Data Customization |
|
| Company Level |
|
| Additional Data Analysis |
|
| Additional Qualitative Data |
|
| Additional Quantitative Data |
|
| Service Level Customization |
|
Report Format Alteration |
|
